Skip to main content

Table 2 Demographic and clinical characteristic of patients included in the study of plasmatic levels of In1-ghrelin and ghrelin in control (n = 30) and PCa patients (n = 20)

From: The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness

Parameter Control (n = 20) PCa (n = 30) p value
Age, yr., mean (SD) 63.8 (9.9) 74.8 (8.1) < 0,0001
Weight, kg, mean (SD) 82.62 (12.8) 78.7 (12.3) 0.29
BMI, mean (SD) 29.8 (4.7) 28,8 (3.6) 0.54
Total PSA, ng/ml, median (IQR) 0.85 (0.44–1.1) 25 (11.1–83.9) < 0,0001
Gleason score, n (%)
 6   8/30 (26,6%) -
 7   9/30 (30%) -
 8   7/30 (23,3%) -
 9   6/30 (20%) -
Acylated In1-ghrelin, pg/mL, median (IQR) 0 (0–0) 4.6 (0–18) 0,03
  1. PCa prostate cancer, Yr year, SD standard desviation, Kg kilogram, cm centimeter BMI body mass index, n number, IQR interquartile range. p-values <0.05 are indicated in italics